These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36660542)

  • 21. Multicenter, prospective, comparative cohort study evaluating the efficacy and safety of alfuzosin 10 mg with regard to blood pressure in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia with or without antihypertensive medications.
    Zhang LT; Lee SW; Park K; Chung WS; Kim SW; Hyun JS; Moon DG; Yang SK; Ryu JK; Yang DY; Moon KH; Min KS; Park JK
    Clin Interv Aging; 2015; 10():277-86. PubMed ID: 25653511
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study.
    Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
    World J Urol; 2019 May; 37(5):867-872. PubMed ID: 30121825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH) in China: results from the China Health and Retirement Longitudinal Study.
    Zhang W; Zhang X; Li H; Wu F; Wang H; Zhao M; Hu H; Xu K
    BMJ Open; 2019 Jun; 9(6):e022792. PubMed ID: 31221864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [PDE5: A new therapeutic target for lower urinary tract symptoms/ benign prostatic hyperplasia combined with erectile dysfunction].
    Xu Z; Jia RP
    Zhonghua Nan Ke Xue; 2018 Apr; 24(4):355-359. PubMed ID: 30168958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relationship between benign prostatic hyperplasia/lower urinary tract symptoms and total serum testosterone level in healthy middle-aged eugonadal men.
    Lee JH; Kim Y; Park YW; Lee DG
    J Sex Med; 2014 May; 11(5):1309-15. PubMed ID: 24612680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The association between anogenital distance and benign prostatic hyperplasia related lower urinary tract symptoms in Chinese aging men.
    Lu Y; Fan S; Song Y; Liu K; Zhou K; Kang J; Wang S; Yang Y; Liu X
    World J Urol; 2021 Jul; 39(7):2645-2653. PubMed ID: 33141318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence and heritability of benign prostatic hyperplasia and LUTS in men aged 40 years or older in Zhengzhou rural areas.
    Yue L; Wang T; Ge Y; Ge M; Zhang C; Hou Q; Wang W; Tian H; Ren B; Du B; Zhang W
    Prostate; 2019 Feb; 79(3):312-319. PubMed ID: 30450670
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a hexanic extract of Serenoa repens (Permixon
    Vela-Navarrete R; Alcaraz A; Rodríguez-Antolín A; Miñana López B; Fernández-Gómez JM; Angulo JC; Castro Díaz D; Romero-Otero J; Brenes FJ; Carballido J; Molero García JM; Fernández-Pro Ledesma A; Cózar Olmos JM; Manasanch Dalmau J; Subirana Cachinero I; Herdman M; Ficarra V
    BJU Int; 2018 Dec; 122(6):1049-1065. PubMed ID: 29694707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Temporary implantable nitinol device (TIND): a novel, minimally invasive treatment for relief of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH): feasibility, safety and functional results at 1 year of follow-up.
    Porpiglia F; Fiori C; Bertolo R; Garrou D; Cattaneo G; Amparore D
    BJU Int; 2015 Aug; 116(2):278-87. PubMed ID: 25382816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug treatment patterns for the management of men with lower urinary tract symptoms associated with benign prostatic hyperplasia who have both storage and voiding symptoms: a study using the health improvement network UK primary care data.
    Hakimi Z; Johnson M; Nazir J; Blak B; Odeyemi IA
    Curr Med Res Opin; 2015 Jan; 31(1):43-50. PubMed ID: 25333647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function.
    Li MK; Garcia L; Patron N; Moh LC; Sundram M; Leungwattanakij S; Pripatnanont C; Cheng C; Chi-Wai M; Loi-Cheong N
    BJU Int; 2008 Jan; 101(2):197-202. PubMed ID: 18005205
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Risk of Sexual Dysfunction and Effectiveness of Treatment of Benign Prostatic Hyperplasia With Severe Lower Urinary Tract Dysfunction With Combination of Dutasteride and Solifenacin.
    Kosilov K; Kuzina I; Kuznetsov V; Gainullina Y; Kosilova L; Karashchuk E; Prokofyeva A; Loparev S
    J Sex Med; 2018 Nov; 15(11):1579-1590. PubMed ID: 30415813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of inflammation in lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) and its potential impact on medical therapy.
    Ficarra V; Rossanese M; Zazzara M; Giannarini G; Abbinante M; Bartoletti R; Mirone V; Scaglione F
    Curr Urol Rep; 2014 Dec; 15(12):463. PubMed ID: 25312251
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal association between the dynamic nature of depression with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH).
    Xie Z; Liu X; Hu Z; Dong C
    BMC Public Health; 2024 Apr; 24(1):1121. PubMed ID: 38654263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serenoa repens, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia.
    Russo A; Capogrosso P; La Croce G; Ventimiglia E; Boeri L; Briganti A; Damiano R; Montorsi F; Salonia A
    Expert Opin Drug Saf; 2016 Dec; 15(12):1661-1670. PubMed ID: 27232207
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].
    Descazeaud A; Barry Delongchamps N; Cornu JN; Azzouzi AR; Buchon D; Benchikh A; Coloby P; Dumonceau O; Fourmarier M; Haillot O; Lebdai S; Mathieu R; Misrai V; Saussine C; de La Taille A; Robert G;
    Prog Urol; 2015 Jun; 25(7):404-12. PubMed ID: 25841758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies.
    Freitas D; Andriole GL; Freedland SJ; Neto BS; Moreira DM
    Urology; 2019 Jul; 129():160-164. PubMed ID: 30914334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of metabolic syndrome on the responsiveness to α1-blocker in men with BPH/LUTS.
    Lee YC; Liu CC; Juan YS; Wu WJ; Li WM; Yeh HC; Wang CJ; Huang CN; Huang CH; Huang SP
    Int J Clin Pract; 2013 Apr; 67(4):356-62. PubMed ID: 23409734
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.
    Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P
    Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.